AnalystBook Research · Company Intelligence

AGENUS INC

AGENNasdaq

Built from AGENUS INC's own SEC filings · updates as new filings land · sources cited throughout

or browse all covered companies

← Research LibraryThe BriefFY2025 10-K · headline figures audited against SEC data

Agenus narrowed its net loss to $3.1M, but revenue quality is royalty-heavy and cash was only $3.0M at year-end.

The read at a glance✓ Audited against SEC data
  • Business mix — Cancer immunotherapy pipelineNote
  • Revenue — Revenue rose 10.4% to $114.2MOK
  • Profitability — Net loss narrowed to $3.1MNote
  • Cash burn — Free cash flow was -$77.2MWatch
  • Balance sheet — Equity deficit was $271.1MWatch
  • Insiders — 0 buys / 0 sellsNote
  • Accounting — Altman-Z distress; Beneish flag; EQ greyWatch

Business

Agenus is a clinical-stage biotechnology company developing immunotherapies for cancer and infectious disease, led by botensilimab alone and with balstilimab.

Where the revenue comes from

Fiscal 2025, as AGENUS INC reports it. History and quarterly detail are in the app.

  • Non Cash Revenue Related To Sale Of Future Royalties$108.6M
  • Non Cash Royalty Revenue$108.6M
  • Pre Commercial Product Revenue$4.2M
  • Revenue$1.0M
  • Other$1.0M

Leadership changes

From AGENUS INC's own filings, the day they're filed.

  • Austin Charette · Director · departureeff. 2026-05-29
  • Garo Armen · Chief Financial Officer · appointmenteff. 2026-01-08
  • Austin Charette · Principal Accounting Officer · appointmenteff. 2026-01-08

Latest filings

  • 8-K · Company announcement2026-08-18
  • 8-K · Company announcement2026-08-13
  • 8-K · Company announcement2026-08-11
  • 10-Q · Quarterly report2026-08-07
  • 8-K · Company announcement2026-08-06
In the full recordFree for 14 days
  • What changed🔒
  • Insider signal🔒
  • Growth quality🔒
  • Margins & accounting🔒
  • Capital allocation🔒
  • Real risks🔒
  • The long arc🔒
  • Company history🔒
  • Main tension🔒
  • The filings, readable — with what changed vs the prior year highlighted🔒
  • Full financial statements, industry-aware, sources cited throughout🔒
  • Forensic score history & components — the trend, not one year🔒
  • Ownership: insider buys/sells, clusters, activist stakes🔒
  • Ana — ask about AGENUS INC, every answer cited to the official filings🔒

Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.

See the full AGEN record — start free

14-day free trial, no credit card. For research purposes only; not investment advice.